Document is current
Any future updates will be listed below
-
Authors
Tang, Joseph
Yates, Adam
Nwoga, Chiaka
Sing’oei, Valentine
Owuoth, John
Otieno, June
Odongo, Hezekiah
Nyariro, Jacob
Otieno, Kennedy
Hickey, Patrick W.
Polyak, Christina S.
Robb, Merlin L.
Crowell, Trevor A. https://orcid.org/0000-0001-5947-265X
,
Adongo, Rachel
Aguttu, Rachel
Akala, Hosea
Ake, Julie
Bondo, Michael
Broach, Erica
Busisa, Christine
Copeland, Nate
Cowden, Jessica
de Souza, Mark
Eller, Leigh Anne
Gogo, Milicent
Hamby, Tyler
Hassen, Zebiba
Hu, Dale
Imbach, Michelle
Juma, Anne
Kasera, Oscar
Li, Qun
Mbuchi, Margaret
Milazzo, Mark
Modjarrad, Kayvon
Ngonda, Eric
Ochola, Jew
Ohore, Roseline
Okumu, Thomas
Omondi, Mary
Ooro, Linnah
Orando, Beatrice
Owira, Victorine
Oyugi, Roselyn
Rono, Eric
Tran, Chi
Turley, Hannah
-
Funding
Funding for this research was provided by:
U.S. National Institute of Allergy and Infectious Diseases (W81XWH-11-2-0174; W81XWH-18-2-004; HT9425-24-3-0004)
- License Information
-
More Information
Article History
Received: 27 May 2025
Accepted: 18 May 2026
First Online: 27 May 2026
Declarations
:
: The RV393 study was reviewed and approved by the Kenya Medical Research Institute Scientific and Ethical Review Unit, Nairobi, Kenya and the Walter Reed Army Institute of Research Institutional Review Board, Silver Spring, Maryland USA. The study was conducted in accordance with the principles described in the International Conference on Harmonization Good Clinical Practice guidelines, the Nuremberg Code, the Belmont Report, the Declaration of Helsinki, and federal regulations regarding the protection of human participants as described in 32 CFR 219 and Army Regulation 70–25. All participants and impartial witnesses of illiterate participants provided written informed consent before screening for study eligibility.
: Not applicable.
: The authors declare no competing interests.
